Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies
Open Access
- 19 June 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 36 (1), 271-274
- https://doi.org/10.1038/s41375-021-01322-1
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic ModelJournal of Clinical Oncology, 2021
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2019
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLLBlood, 2018
- Ventricular arrhythmias and sudden death in patients taking ibrutinibBlood, 2017
- Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLLLeukemia, 2017
- Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLLLeukemia, 2017
- Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective studyBritish Journal of Haematology, 2016
- Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemiaBlood, 2015
- Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximabLeukemia, 2013
- Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trialThe Lancet, 2007